What the Curium acquisition means for Lantheus investors

Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) in a transaction valued at up to US$8b, offering US$102.50 in cash per share at closing plus contingent value rights worth up to US$12.00 per share.

The contingent value rights are linked to commercial milestones for key Lantheus products through 2030. Until the deal closes, currently expected in the first half of 2027 subject to approvals, Lantheus will remain an independent, publicly traded company.

For you as an investor, this means the stock is now closely tied to the proposed cash offer and the probability and timing of the transaction completing. It also introduces potential additional upside through the contingent value rights if specified product milestones are met.

Lantheus Holdings shares now trade at US$100.98, with the 1-year total shareholder return of 80.10% and 5-year total shareholder return above 3x reflecting strong long term gains. However, the 1-month share price return of a 4.41% decline suggests recent momentum has cooled following the Curium deal announcement and the suspension of 2026 guidance.

If this M&A story has you thinking about where else growth and re-rating potential might appear, it could be worth checking out 43 healthcare AI stocks as a starting point for other healthcare ideas.

The share price now sits close to Curium's cash offer, while the intrinsic value estimate suggests a wide gap. Does the risk and potential reward from here still skew in favour of owning Lantheus Holdings stock?

Most Popular Narrative: 3% Undervalued

The most followed narrative on Lantheus Holdings pegs fair value at $104.08, only modestly above the last close at $100.98. This points to a relatively tight valuation gap based on detailed earnings and cash flow assumptions.

The analysts have a consensus price target of $104.08 for Lantheus Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $117.0, and the most bearish reporting a price target of just $76.0.

Want to see what sits behind that tight spread between price and fair value? The narrative references assumptions about top line growth, firmer margins and a lower future earnings multiple than many peers. This combination of factors leads to the $104.08 value.

Result: Fair Value of $104.08 (UNDERVALUED)

However, there are still clear risks for Lantheus Holdings if PYLARIFY faces ongoing pricing pressure or if recent acquisitions deliver only limited earnings contribution compared with expectations.

Next Steps

With sentiment on Lantheus Holdings split between deal certainty and fundamental value, it makes sense to check the data yourself and move quickly before views settle. To zero in on what the market sees as the main upsides, take a closer look at the 4 key rewards

Looking for more Lantheus and healthcare investment ideas?

Do not stop with Lantheus Holdings. The market will keep moving whether you act or not, so consider giving yourself more quality options before the next wave of headlines.

• Target fresh upside potential by scanning for companies priced below what their fundamentals suggest using the 51 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with stronger finances and sturdier balance sheets through the solid balance sheet and fundamentals stocks screener (48 results).
• Strengthen your income stream by reviewing companies that combine higher yields with staying power using the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.